From Nasdaq:

Specialised Therapeutics Asia Pte Ltd. has signed an exclusive agreement with Danish company Ascendis Pharma A/S for distribution and commercialization of three endocrinology therapies in Australia and select South-East Asia countries. This will include the weekly injectable paediatric human growth hormone treatment SKYTROFA, hypoparathyroidism treatment YORVIPATH, and investigational achondroplasia therapy TransCon CNP. The agreement spans Specialised Therapeutics’ key regions of Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam. Two of the products included in this agreement are already internationally approved. SKYTROFA is already approved in the U.S. and the E.U., and YORVIPATH is already approved in the E.U. TransCon CNP is in development by Ascendis Pharma.



Read more: Specialised Therapeutics Signs Deal With Ascendis For Commercialization Of 3 Endocrinology Therapies